
    
      Single-center randomized controlled trial, single-blind, including patient with an acute
      coronary syndrome confirmed, to measure the anti-Xa activity between H0 and H4.the study was
      done on two groups ; ENOXA® group : In this case the patient is given an injection of
      enoxaparin ( ENOXA® ; UNIMED Laboratories) intravenously. Curative dose (100 IU/10 kg).

      Control group ( LOVENOX ® ):

      In this case the patient receives LOVENOX intravenous injection curative dose of 100 kg IU/10
      .
    
  